INTERVIEW | Dr James Campbell on Proactive
0
Patrys CEO and MD, Dr James Campbell, was interviewed by Proactive’s Andrew Scott to discuss the importance of today’s announcement that…
PAT-DX1 Engineering Run Update
Patrys’ appointed Contract Development Manufacturing Organisation (CDMO) has successfully completed specification testing of PAT-DX1 drug substance produced in the recently-completed…
New Research Grant For Deoxymabs in Metastatic Breast Cancer
Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian…
PAT-DX1 Improves Survival in Animal Model of Brain Cancer
Patrys is pleased to share promising new preclinical research results today. A new animal study has found that PAT-DX1, in…
Retirement of Non-Executive Chair
Patrys has today announced that the Company’s long-standing Chair, Mr John Read, will be retiring as the Non-Executive Chair, and…
Quarterly Activities Report & 4C – 30 June 2022
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30…
PAT-DX1 Engineering Run Successfully Completed
Patrys has today announced a positive update on the second engineering run for its lead asset PAT-DX1, a critical step…
Patrys Investor Newsletter
Our latest Investor Newsletter is here. This edition includes an update from Patrys CEO and MD, Dr James Campbell; a…
Patrys on Channel 7 News
Channel 7 News Journalist Jackie Quist recently interviewed Patrys CEO and MD, Dr James Campbell, together with Telethon Kids Institute’s,…
PAT-DX1 Significantly Improves Survival in Animal Model of Pancreatic Cancer
Patrys has today announced the publication of new data from a series of studies by our collaborators Dr James Hansen,…